 |
| Editorial |  Top |
|
 |
 |
The responsibilities of growing up p225
doi:10.1038/nbt0306-225
Full text | PDF
(86K)
|
|
| News | Top |
|
 |
|
| News Feature |
|
|
|
Finding the moral high ground pp237 - 239
Ken Howard Wilan
& Laura DeFrancesco
Published online: 01 March 2006 | doi:10.1038/nbt0306-237
Abstract | Full text | PDF
(141K)
|
|
|
|
Where the money is pp240 - 242
Michael Fitzgerald
doi:10.1038/nbt0306-240
Abstract | Full text | PDF
(224K)
|
|
| Opinion and Comment | Top |
|
|
|
| Commentary |
|
|
|
Navigating the future(s) of biotech intellectual property pp249 - 251
Kenneth Neil Cukier
Published online: 08 March 2006 | doi:10.1038/nbt0306-249
Abstract | Full text | PDF
(186K)
|
|
|
|
Fates intertwined pp252 - 254
Garth J S Cooper
doi:10.1038/nbt0306-252
Abstract | Full text | PDF
(114K)
|
|
|
|
Who took the tech out of biotech? pp255 - 256
Elizabeth Silverman
doi:10.1038/nbt0306-255
Abstract | Full text | PDF
(113K)
|
|
|
|
Price controls: preparing for the unthinkable pp257 - 260
Stephan Herrera
doi:10.1038/nbt0306-257
Abstract | Full text | PDF
(212K)
|
|
|
|
Crystal gazing: biotech's financial outlook p261
Eric Schmidt
& David J Strupp
doi:10.1038/nbt0306-261a
Abstract | Full text | PDF
(205K)
|
|
|
|
From oligos to Oprah—the consumer and biotech p265
Paul Oestreicher, Tim Warner
& John Mack
doi:10.1038/nbt0306-265a
Abstract | Full text | PDF
(115K)
|
|
|
|
Biogenerics at the crossroads p268
Carole S Ben-Maimon
& Rob Garnick
doi:10.1038/nbt0306-268a
Abstract | Full text | PDF
(121K)
|
|
|
|
Ten years of biotech gaffes pp270 - 273
John Hodgson
Published online: 08 March 2006 | doi:10.1038/nbt0306-270
Abstract | Full text | PDF
(215K)
|
|
|
|
Whither agbiotechnology? pp274 - 276
L Val Giddings
doi:10.1038/nbt0306-274
Abstract | Full text | PDF
(128K)
|
|
|
|
Convergence in biomedical technology p277
Ascher Shmulewitz, Robert Langer
& John Patton
doi:10.1038/nbt0306-277a
Abstract | Full text | PDF
(202K)
|
|
|
|
Welcome to the body-wide web pp282 - 283
David Shenk
doi:10.1038/nbt0306-282
Abstract | Full text | PDF
(113K)
|
|
 |
|
| Investor's Lab |
|
|
|
A rollercoaster ride p284
Tom Jacobs
doi:10.1038/nbt0306-284
Full text | PDF
(73K)
| Supplementary Information |
|
| Features | Top |
|
|
|
Ethical decision-making in bioscience firms pp285 - 290
David Finegold
& Allison Moser
doi:10.1038/nbt0306-285
Abstract | Full text | PDF
(326K)
| Supplementary Information |
|
|
|
Who's who in biotech pp291 - 300
K S Jayaraman, Sabine Louët, Kendall Powell, John Ransom, Cormac Sheridan, Brian Vastag
& Emily Waltz
Published online: 02 March 2006 | doi:10.1038/nbt0306-291
Abstract | Full text | PDF
(508K)
|
|
|
|
Ten years of Nature Biotechnology research p301
Monya Baker
doi:10.1038/nbt0306-301a
Abstract | Full text | PDF
(512K)
|
|
|
|
Off the beaten path pp309 - 315
Jonathan Buckley, Jorge Gatica, Mark Tang, Halla Thorsteinsdóttir, Alok Gupta, Sabine Louët, Min-Chol Shin
& Mark Wilson
Published online: 02 March 2006 | doi:10.1038/nbt0306-309
Abstract | Full text | PDF
(373K)
|
|
|
|
| Patents |
|
|
|
Biotech patents: looking backward while moving forward pp317 - 319
Rebecca S Eisenberg
doi:10.1038/nbt0306-317
Abstract | Full text | PDF
(187K)
|
|
|
|
Bayh-Dole: if we knew then what we know now pp320 - 323
Sara Boettiger
& Alan B Bennett
doi:10.1038/nbt0306-320
Abstract | Full text | PDF
(182K)
|
|
Top |
|
|
